


# GSK in Belgium

## Who are we?

We are a global biopharma company with a purpose to **unite science, technology and talent to get ahead of disease together.**

We aim to positively impact the health of **2.5 billion people** over the next 10 years.





**Rixensart** – This historic site houses our largest vaccine research and development (R&D) unit. The names of our vaccines developed here end with **-RIX**.

We have acquired unique international expertise in the fields of adjuvants and bacterial and viral infections.

---

> 20

candidate vaccines in research & development as well as >20 scientific collaborations with Belgian universities and research centres.

---

37

clinical trials in 2022 in Belgium, involving 1,800 volunteers.

---

> €1

billion invested in R&D in 2022.

---

**Gembloux** – Construction of a new, unique, ultra-modern centre dedicated to the storage and export of our vaccines.



# Belgium: the heart of our vaccines

We have 3 important vaccines sites in Belgium.

Our infrastructure represents **the largest, integrated industrial network of vaccines**, from early discovery, through development, all manufacturing steps and export.



**Wavre** – This site is the heart of our vaccines business. It is **the largest vaccine production site in the world**, equivalent to

**70** football fields.

Our colleagues responsible for the distribution of our vaccines and medicines in Belgium and in Luxembourg are also located in Wavre.

Our vaccines are exported to >160 countries.

We are the largest Walloon exporter: our vaccines account for >10% of exports.


70% of manufacturing time is dedicated to quality controls.



## What we do

We produce **innovative vaccines** and **specialty medicines** to prevent and treat diseases.

Our research focuses on the science of the immune system, human genetics and cutting-edge technologies.



## Our collaborators in Belgium

Our **Rixensart**, **Wavre** and **Gembloux** sites count **9,000** collorabators, including 1,800 scientific researchers, representing >80 nationalities.

**22%**  
workers.

**35%**  
employees.

**43%**  
managers.

## Our sustainable development strategy

A healthy planet for healthy people.

To support GSK's vision, we focus on 4 areas in Belgium: **Energy & Carbon**, **Water**, **Waste** and **Biodiversity**.

### Our ambitions for 2030:

- to be carbon neutral and
- have a net positive impact on nature



## Our commitment to Global Health

GSK will invest >€1 billion over the next 10 years to accelerate health-focused R&D in developing countries.

We have always been **top of the Access to Medicine Index** since its creation.

Every minute, a child dies of malaria in Sub-Saharan Africa. Our **malaria vaccine** is the 1<sup>st</sup> vaccine approved and the only vaccine against a human parasite. It was developed in Rixensart, and is currently manufactured there. This vaccine was also amongst the finalists of the *essencia* Innovation Award in 2022.

GSK is one of the main suppliers of vaccines for

unicef 

Gavi   
The Vaccine Alliance

# Ahead together

Want to find out more?

 [be.gsk.com](https://be.gsk.com)

The GSK logo is displayed in a bold, sans-serif font. The letters 'G' and 'S' are a darker orange, while the 'K' is a lighter, more vibrant orange. The letters are closely spaced and have a slight shadow effect.

External Communication and Public Affairs:

Elisabeth Van Damme | [elisabeth.evandamme@gsk.com](mailto:elisabeth.evandamme@gsk.com) | +32 (0)478 27 26 41

GSK Vaccines | Avenue Fleming 20 – 1300 Wavre, Belgium

©GSK December 2022

Design: [visible.be](https://visible.be) (23955)

Printed on FSC certified paper

CREDIT MIX SGSCH-COC-006801